1
|
Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Benatsou B, Bonastre J, Koscielny S. Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. Ann Oncol 2016; 27:1922-8. [PMID: 27502701 DOI: 10.1093/annonc/mdw280] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 07/06/2016] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Dynamic contrast-enhanced ultrasonography (DCE-US) has been used for evaluation of tumor response to antiangiogenic treatments. The objective of this study was to assess the link between DCE-US data obtained during the first week of treatment and subsequent tumor progression. PATIENTS AND METHODS Patients treated with antiangiogenic therapies were included in a multicentric prospective study from 2007 to 2010. DCE-US examinations were available at baseline and at day 7. For each examination, a 3 min perfusion curve was recorded just after injection of a contrast agent. Each perfusion curve was modeled with seven parameters. We analyzed the correlation between criteria measured up to day 7 on freedom from progression (FFP). The impact was assessed globally, according to tumor localization and to type of treatment. RESULTS The median follow-up was 20 months. The mean transit time (MTT) evaluated at day 7 was the only criterion significantly associated with FFP (P = 0.002). The cut-off point maximizing the difference between FFP curves was 12 s. Patients with at least a 12 s MTT had a better FFP. The results according to tumor type were significantly heterogeneous: the impact of MTT on FFP was more marked for breast cancer (P = 0.004) and for colon cancer (P = 0.025) than for other tumor types. Similarly, the differences in FFP according to MTT at day 7 were marked (P = 0.004) in patients receiving bevacizumab. CONCLUSION The MTT evaluated with DCE-US at day 7 is significantly correlated to FFP of patients treated with bevacizumab. This criterion might be linked to vascular normalization. AFSSAPS NO 2007-A00399-44.
Collapse
Affiliation(s)
- N Lassau
- Gustave Roussy, Université Paris-Saclay, Imaging Department, Villejuif, and IR4M, Centre National de la Recherche Scientifique, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - B Coiffier
- Gustave Roussy, Université Paris-Saclay, Imaging Department, Villejuif, and IR4M, Centre National de la Recherche Scientifique, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - M Kind
- Imaging Department, Institut Bergonié, Bordeaux
| | - V Vilgrain
- Radiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Clichy
| | - J Lacroix
- Radiology Department, Centre François Baclesse, Caen
| | - M Cuinet
- Radiology Department, Centre Léon Bérard, Lyon
| | - S Taieb
- Radiology Department, Centre Oscar Lambret, Lille
| | - R Aziza
- Radiodiagnostics Department, Centre Claudius Regaud, Toulouse
| | - A Sarran
- Imaging Department, Institut Paoli Calmettes, Marseille
| | | | - B Gallix
- Department of Abdominal and Digestive Imaging, Hôpital Saint-Eloi, Montpellier and Department of Radiology, McGill University Health Center, Montreal, Canada
| | - O Lucidarme
- Radiology Department, CHU La Pitié-Salpêtrière, Paris
| | - Y Ptak
- Radiodiagnostics Department, Centre Jean Perrin, Clermont-Ferrand
| | - L Rocher
- Radiology Department, CHU Bicêtre, Le Kremlin-Bicêtre
| | - L M Caquot
- Radiodiagnostics and Imaging Department, Institut Jean Godinot, Reims
| | - S Chagnon
- Radiology Department, Hôpital Ambroise Paré, Boulogne-Billancourt
| | - D Marion
- Radiology Department, CHU Hôtel-Dieu, Lyon
| | - A Luciani
- Radiology Department, CHU Henri Mondor, Créteil
| | - S Feutray
- Radiology Department, Centre Georges-François Leclerc, Dijon
| | | | - B Benatsou
- Gustave Roussy, Université Paris-Saclay, Imaging Department, Villejuif, and IR4M, Centre National de la Recherche Scientifique, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - J Bonastre
- Service biostatistique et épidémiologie, Gustave Roussy and CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris-Sud Univ., Villejuif, France
| | - S Koscielny
- Service biostatistique et épidémiologie, Gustave Roussy and CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris-Sud Univ., Villejuif, France
| |
Collapse
|
2
|
Jankowski C, Hudry D, Vaillant D, Varbedian O, Mejean N, Guy F, Feutray S, Coutant C. Evaluation of axillary involvement by ultrasound-guided lymph node biopsy: A prospective study. ACTA ACUST UNITED AC 2015; 43:431-6. [DOI: 10.1016/j.gyobfe.2015.04.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 04/17/2015] [Indexed: 01/28/2023]
|
3
|
Vulquin N, Feutray S, Peignaux-Casasnovas K, Humbert O, Créhange G, Truc G, Maingon P, Martin É. Évaluation radiologique de la réponse tumorale après radiothérapie pulmonaire en conditions stéréotaxiques. Cancer Radiother 2014; 18:414-9. [DOI: 10.1016/j.canrad.2014.07.157] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/24/2014] [Indexed: 12/25/2022]
|
4
|
Guiu S, Arnould L, Gauthier M, Favier L, Tixier H, Feutray S, Fumoleau P, Coudert B. Abstract P1-11-02: Pathologic Response and Survival after Neoadjuvant Therapy for Breast Cancer: A 30-Year Single-Center Study. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative (TN) and HER2-positive (HER2+) breast cancers have usually a worse prognosis than the luminal subtypes despite an initial chemosensitivity. The aim of this single-center study was to compare pathologic complete response (pCR) rates, disease-free (DFS) and overall (OS) survivals rates after neoadjuvant therapy according to both HER2 and hormonal status.
Patients and Methods: Between 1978 and 2008, 461 patients were treated with neoadjuvant therapy at Georges-François Leclerc Cancer Center. Patients were classified in 3 groups: TN (defined by both estrogen/progesterone receptor negative and HER2 negative), HER2+ (3+ in immunohistochemistry or 2+ with amplification in fluorescence in situ hybridization) and HR+ (estrogen and/or progesterone receptor positive without HER2 overexpression or amplification). Median follow-up lasted 7.1 years [range: 0.49-29.8]. Number of events was 213 for DFS calculation and number of deaths was 150 for OS calculation. Response rates were compared using Chi2-tests. Survivals were calculated according to Kaplan-Meier and compared using log-rank tests. Univariate and multivariate Cox proportional hazards models were performed. The multivariate models were internally validated using bootstrapping (400 replications). Results: 86 of 461 were TN (19%), 125 were HER2+ (27%) and 250 were HR+ (54%). Patients with TN and HER2+ breast cancer were younger (p=0.032), had more inflammatory cancer (p=0.033) and aggressive tumors (SBR 3, P<0.001). Pathologic complete response rate (grades 1 and 2 of Chevallier's classification) was significantly higher for TN (22.4%) and HER2+ (29.6%) than in for HR+ (3.6%) (P<0.001). In univariate analysis, the following characteristics were related to a higher pCR rate: smaller clinical size (p=0.029), higher grade tumor (p=0.001) and HER2+ or TN status (P<0.001). In multivariate analysis, only tumor grade (p=0.022) and hormonal/HER2 status (p=0.003) were independently associated with pCR.
Median DFS was 4.4years for TN, 7.8y for HER2+ and 9y for HR+ (p=0.003, logrank test). In HER2+ patients, neoadjuvant trastuzumab was associated with a higher DFS (8.65 vs. 3.24y, p=0.002). Patients who achieved a pCR had a higher DFS (p=0.015) than those with only partial pathologic response (median=6.9y vs. 12.7y). In multivariate analysis, pCR remained significant (HR (bootstrapping) = 0.5 [IC95%, 0.28-0.91], p=0.023).
Median OS was 6.4y for TN, 15.1y for HER2+ and 13.1y for HR+ (P<0.001, logrank test). Patients who achieved a pCR had a higher OS (p=0.004) than those with non-pCR (median=not reached vs. 10.9y). In multivariate analysis, OS was lower for patients>50years (HR (bootstrapping)=1.79 [IC95%, 1.23-2.60], p=0.002), in TN subgroup (HR=2.46 [IC95%, 1.5-4.03], p=0.001) and when pCR was not achieved (HR=0.28, [IC95%, 0.12-0.66], p=0.003).
Conclusion: After neoadjuvant therapy, TN breast cancers have a worse prognosis despite their initial chemosensitivity with a high pCR rate. HER2+ have a lower DFS than HR+/HER2- breast cancers but a better OS, mainly due to anti-HER2 targeted therapies. Pathologic complete response is a strong independent prognostic factor after neoadjuvant therapy for breast cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-11-02.
Collapse
Affiliation(s)
- S Guiu
- Georges-François Leclerc Cancer Center, Dijon, France
| | - L Arnould
- Georges-François Leclerc Cancer Center, Dijon, France
| | - M Gauthier
- Georges-François Leclerc Cancer Center, Dijon, France
| | - L Favier
- Georges-François Leclerc Cancer Center, Dijon, France
| | - H Tixier
- Georges-François Leclerc Cancer Center, Dijon, France
| | - S Feutray
- Georges-François Leclerc Cancer Center, Dijon, France
| | - P Fumoleau
- Georges-François Leclerc Cancer Center, Dijon, France
| | - B. Coudert
- Georges-François Leclerc Cancer Center, Dijon, France
| |
Collapse
|
5
|
Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Moluçon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2005; 17:409-14. [PMID: 16332965 DOI: 10.1093/annonc/mdj096] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Trastuzumab plus chemotherapy has become the standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Trastuzumab-based pre-operative systemic (neo-adjuvant) therapy (PST) also appears promising, warranting further investigation. PATIENTS AND METHODS Patients with HER2-positive, stage II/III non-inflammatory, operable breast cancer requiring a mastectomy (but who wished to conserve the breast) received weekly trastuzumab and 3-weekly docetaxel for six cycles before surgery. The primary end point was pathological complete response (pCR) rate, determined from surgical specimens. RESULTS Thirty-three patients were enrolled. The majority (79%) had T2 tumors, with 42% being N1/2. Twenty-nine patients completed six cycles of therapy and one patient withdrew prematurely due to progressive disease. A complete or partial objective clinical response was seen in 96% (73% and 23%, respectively) of patients. Surgery was performed in 30 patients, breast conserving in 23 (77%). In an intention-to-treat analysis, tumor and nodal pCR was seen in 14 (47%) patients. Treatment was generally well tolerated. Grade 3/4 neutropenia occurred in 85% of patients while febrile neutropenia was encountered in 18%. Only three patients withdrew prematurely due to toxicity. No symptomatic cardiac dysfunction was reported. CONCLUSIONS PST with trastuzumab plus docetaxel achieved promising efficacy, with a high pCR rate and good tolerability, in women with stage II or III HER2-positive breast cancer.
Collapse
Affiliation(s)
- B P Coudert
- Oncology, Surgery, Radiology CAC GF Leclerc, Dijon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Benoit L, Lacombe E, Feutray S, Favoulet P, Boulleret C, Fraisse J, Cuisenier J. [Role of microbiopsy in diagnostic and therapeutic approach of mammary suspect microcalcification]. Ann Chir 2003; 128:368-72. [PMID: 12943832 DOI: 10.1016/s0003-3944(03)00112-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE To determine the sensibility, the specificity, the positive and negative predictive values of microcalcifications detection by core needle biopsy and intra-operative pathologic examination. MATERIALS AND METHODS A hundred and one patients (between 1998 and 1999) were investigated in this retrospective study. The initial presentation was breast microcalcifications without palpable tumour. The mean age of patients was 55 (34-79) years. Mammography was performed in 3 standard projections. All suspect microcalcifications were recommended for surgical excision. In the others cases, 5 core biopsies were taken of the lesion. Needle guidance was accomplished by means of either dedicated stereotaxic device or ultrasound equipment. All biopsies were performed with a biopsy device fitted with 14 G needles. The mean follow-up period was 3 years. RESULTS Clinical or surgical follow-up was available in 101 lesions. Only 4 benign lesions did not have surgery. The 97 remaining were subsequently excised. Pathologic study showed cancer in 38 (39%) lesions, carcinoma in-situ in 14 lesions, and benign disease in 45 lesions. There was 1 false-negative biopsy. The specificity and sensitivity of percutaneous biopsy diagnosis were 73,6 and 93,7% respectively. Intra-operative pathologic diagnoses were concordant in 77% of 30 cases. Discordance occurred in 2 cases of atypical hyperplasia with a single false-negative result for a carcinoma that led to an additional surgical procedure. Positive and negative predictive values of intra-operative pathologic diagnosis were 82 and 100% respectively. CONCLUSION Needle biopsy findings are accurate and allow definitive therapeutic surgery, including mastectomy.
Collapse
Affiliation(s)
- L Benoit
- Service de chirurgie, centre G.-F.-Leclerc, 1, rue du professeur Marion, BP 77980, 21079 Dijon, France.
| | | | | | | | | | | | | |
Collapse
|
7
|
Barillot I, Horiot JC, Maingon P, Bone-Lepinoy MC, Vaillant D, Feutray S. Maximum and mean bladder dose defined from ultrasonography. Comparison with the ICRU reference in gynaecological brachytherapy. Radiother Oncol 1994; 30:231-8. [PMID: 8209007 DOI: 10.1016/0167-8140(94)90463-4] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The reference bladder dose for gynaecological intracavitary brachytherapy (BT), as defined by the ICRU 38 Report, is often criticised as it is seldom representative of the highest bladder dose nor it gives an idea of the area exposed to a significant dose. Since November 1990, ultrasound measurements are routinely made in order to determine the actual dose delivered to the bladder of each patient. The technique was as follows. (1) the bladder is filled up with 150-200 cm3 of sterile isotonic saline. (2) The intrauterine position of the tube is checked. (3) The bladder anatomy is controlled. (4) Points of measurements are identified: ICRU bladder reference, minimum distance between bladder mucosa, uterine tube and other similar measurements taken every 15 mm along the radio-active line. Maximum and mean doses are calculated at the sagittal plane. Measurements are performed by moving the transducer along the skin of the patient and included in the calculation of dose distribution. Doses delivered to each relevant point are compared. This enables determination to be made of the differences between the ICRU and the doses actually observed at the bladder wall with aid of ultrasonography. BT applications were checked in 58 patients (69 measurements). The method was feasible in all cases. The comparison between ICRU dose from orthogonal films and the ICRU dose from ultrasonography resulted in a 90% accuracy. The maximum and mean doses for utero-vaginal BT are higher than the ICRU dose in 75% of cases (range, 2-8). Measurements are now abandoned for vaginal applications as the ICRU dose only could be measured.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- I Barillot
- Service de Radiothérapie, Centre de lutte contre le cancer Georges-François Leclerc, Dijon, France
| | | | | | | | | | | |
Collapse
|
8
|
Barillot I, Horiot J, Maingon P, Bone-Lepinoy M, Vaillant D, Feutray S. Maximum and mean bladder dose defined from ultrasonography, comparison with the ICRU reference in gynaecological brachytherapy. Med Dosim 1994. [DOI: 10.1016/0958-3947(94)90067-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|